EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate

Abhinav Sharma, Adnan Fatfat, Ishaan Batish, Md Shahrier Amin, LaTonya J Hickson, Nabeel Aslam, Shane A Bobart

Glomerular Diseases · 22.06.2026 · 6 (1) · 279-284

DOI: 10.1159/000553107 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Glomerular Diseases, online erschienen am 22.06.2026. Verfasst von Abhinav Sharma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IgA nephropathy (IgAN) is a common cause of chronic kidney disease (CKD) worldwide. However, patients with advanced CKD and significant fibrosis on biopsy have limited treatment options, and clinical trials studying targeted-release budesonide have excluded individuals with low estimated glomerular filtration rate (eGFR). Case Presentation: We report a case of a 36-year-old male with biopsy-proven crescentic IgAN, initially diagnosed 3 years prior, who presented with progressive renal dysfunction and persistent proteinuria despite prior treatment with immunosuppression, including corticosteroids and rituximab. At evaluation, serum creatinine was 2.86 mg/dL with an eGFR of 28 mL/min/1.73 m2, urine protein-to-creatinine ratio was 1.64 grams/day, and microscopic hematuria was present. Repeat kidney biopsy demonstrated significant chronic changes with severe interstitial fibrosis and tubular atrophy. The Oxford classification score was M1, E1, S1, T2, C1. Targeted-release budesonide was initiated, after which hematuria resolved within 1 month, proteinuria decreased significantly reaching 0.29 g/day, and kidney function improved with a serum creatinine of 2.24 mg/dL and eGFR of 38 mL/min/1.73 m2 at 8 months into treatment. The patient tolerated therapy without major adverse events.

Conclusion

This case demonstrates clinically meaningful improvement in both proteinuria and renal function following treatment with targeted-release budesonide, despite advanced chronicity but with disease activity and low eGFR, a population that remains underrepresented in clinical trials and prospective studies. Our findings highlight the importance of repeat biopsy and future studies addressing the potential benefit of targeted-release budesonide in select patients with advanced IgAN, who may retain a therapeutically targetable inflammatory component.

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathyPathologyProgressive renal diseaseProteinuriaTargeted-release budesonide

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.

Zitieren

APA

Sharma, A., Fatfat, A., Batish, I., Amin, M. S., Hickson, L. T. J., Aslam, N., & Bobart, S. A. (2026). How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate. Glomerular Diseases, 6(1), 279-284. https://doi.org/10.1159/000553107

Vancouver

Sharma A, Fatfat A, Batish I, Amin MS, Hickson LTJ, Aslam N, et al. How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate. Glomerular Diseases. 2026;6(1):279-284. doi:10.1159/000553107

BibTeX
@article{Sharma2026,
  author = {Sharma, Abhinav and Fatfat, Adnan and Batish, Ishaan and Amin, Md Shahrier and Hickson, LaTonya J and Aslam, Nabeel and Bobart, Shane A},
  title = {How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate},
  journal = {Glomerular Diseases},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {279--284},
  doi = {10.1159/000553107}
}
Kostenlos starten →